Dietary Intake and Nutrient Status of Children With ADHD

February 13, 2007 updated by: University of British Columbia

Dietary Intake and Nutrient Status of Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Assess the dietary intake of children aged 6-12 years by means of a 24-hour recall and 3-day food record and asses the nutrient status of Vitamin B6, serum ferritin, serum zinc and serum copper of the same children by means of standard laboratory assessments.

Study Overview

Status

Completed

Conditions

Detailed Description

  • To document the use of vitamin and vitamin-mineral supplements
  • To determine the percent consumption of low nutrient density (LND) foods
  • To compare the dietary intake of ADHD children with the established standards of the Dietary Reference Intakes (DRIs)
  • To compare the dietary intake of children with ADHD to the dietary recommendations of Canada's Food Guide for Healthy Eating
  • To determine whether dietary intake is moderated by drug treatment
  • To assess the pyridoxal-5'-phosphate (PLP), serum ferritin, serum zinc, and serum copper status of ADHD by standard laboratory blood test
  • to measure height and weight in ADHD children

Study Type

Observational

Enrollment

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • British Columbia
      • Vancouver, British Columbia, Canada
        • Provincial ADHD Program, BC Children's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 12 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Primary diagnosis of ADHD
  • Age 6-12 years inclusive

Exclusion Criteria:

  • No use of medication that affects dietary intake (eg. Risperdal)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of British Columbia

Collaborators

Eli Lilly and Company

Investigators

  • Principal Investigator: Margaret D. Weiss, MD, University of British Columbia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2006

Study Completion

January 1, 2007

Study Registration Dates

First Submitted

February 13, 2007

First Submitted That Met QC Criteria

February 13, 2007

First Posted (Estimate)

February 14, 2007

Study Record Updates

Last Update Posted (Estimate)

February 14, 2007

Last Update Submitted That Met QC Criteria

February 13, 2007

Last Verified

February 1, 2007

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • H05-70464
  • W05-0185

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Attention Deficit Hyperactivity Disorder

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe